Bisphosphonates
Drug Safety Update
December 2015: Bisphosphonates and very rare reports of osteonecrosis of the external auditory canal. See also see BNF for safety guidance.
June 2011: Bisphosphonates and atypical femoral fractures. See also see BNF for safety guidance.
April 2010: Intravenous zoledronic acid: adverse effects on renal function
November 2009: Bisphosphonates and osteonecrosis of the jaw. See also see BNF for safety guidance.
July 2008: Bisphosphonates and atrial fibrillation
National guidance
TA464 Bisphosphonates for treating osteoporosis, updated July 2019
National Osteoporosis Guideline Group (NOGG) Clinical guideline for the prevention and treatment of osteoporosis
| Pack |
|---|
| 28 tablet (2 x 14 tablets) |
| Pack |
|---|
| 4 tablet |
| Pack |
|---|
| 28 tablet (2 x 14 tablets) |
| Pack |
|---|
| 4 tablet |
An option for osteoporosis only if the patient meets NICE TA464 criteria
| Pack |
|---|
| 1 tablet |
| 3 tablet |
| Pack |
|---|
| 1 pre-filled disposable injection |
| Pack |
|---|
| 4 ampoule |
| Pack |
|---|
| 2 ampoule |
| Pack |
|---|
| 1 ampoule |
- On Formulary Preferred
- On Formulary Second Line
- On Formulary Third Line
- Specialist Initiation
- Secondary Care Only
- Not Approved for Formulary